Alnylam Pharmaceuticals: Promising Advancements in Alzheimer’s Treatment with RNA Interference Therapeutics
Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Alnylam Pharma (ALNY – Research Report), boosting the price target to ...
Alnylam Pharmaceuticals: Strategic Positioning and Growth Opportunities Reinforce Buy Rating Amidst Competitive ATTR-CM Market
Canaccord Genuity analyst Whitney Ijem maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) yesterday and set a price target of ...
FierceBiotech12d
Intellia's CRISPR and Alnylam's RNAi data drops present contrasting visions for cardiomyopathy care
But the incumbents look set to fight to hold on to the market, with Alnylam Pharmaceuticals sharing early-phase data on its ...
GlobalData on MSN11d
Alnylam reveals trial outcomes of nucresiran for ATTR amyloidosis treatment
The study showed significant reductions in serum TTR levels in subjects after a single dose, with sustained effects over time ...
William Blair Reiterates “Outperform” Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY)
William Blair reiterated their outperform rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a ...
Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Piper Sandler 36th Annual Healthcare ...
Investing4d
Alnylam shares retain Buy rating as analyst sees strong market for multiple ATTR-CM treatments
On Tuesday, Canaccord Genuity maintained a Buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY), with a price target of $384.00. The firm's analyst commented on recent developments in the ...
BioSpace4d
Days After BridgeBio Approval, FDA Agrees to Review Alnylam’s Amvuttra in ATTR-CM
The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, ...
Investing5d
Alnylam reiterates stock target, outperform rating post Attruby FDA nod
On Monday, BMO Capital maintained its optimistic outlook on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY), reiterating an Outperform rating with a $300.00 price target. The firm's confidence is ...
Charles Schwab Investment Management Inc. Buys 16,756 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Charles Schwab Investment Management Inc. increased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – ...
Check Out What Whales Are Doing With ALNY
Delving into the details, we found 5% of traders were bullish, while 84% showed bearish tendencies. Out of all the trades we spotted, 14 were puts, with a value of $931,387, and 5 were calls, valued ...
Investing3d
Alnylam shares retain Buy rating as analyst sees strong market for multiple ATTR-CM treatments
On Tuesday, Canaccord Genuity maintained a Buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY), with a price target of $384.00. The firm's analyst commented on recent developments in the ...